On Nov. 13, 2017, the Department of Transportation (DOT) published a final rule that, among other items, expands DOT’s current drug testing panel to include certain semi-synthetic opioids (i.e., hydrocodone, oxycodone, hydromorphone, oxymorphone). Testing for methylenedioxyethylamphetamine (MDEA) has been removed while methylenedioxyamphetamine (MDA) has been added as an initial test analyte.
The final rule also clarifies existing drug testing program provisions and definitions, makes technical amendments and removes the requirement for employers and Consortium/Third Party Administrators to submit blind specimens. The final rule becomes effective Jan. 1, 2018.
“The opioid crisis is a threat to public safety when it involves safety-sensitive employees involved in the operation of any kind of vehicle or transport,” said DOT Secretary Elaine L. Chao. “The ability to test for a broader range of opioids will advance transportation safety significantly and provide another deterrence to opioid abuse, which will better protect the public and ultimately save lives.”
Click here to read more from DOT.
Click here to read the final rule as published in the Federal Register.
Related News
- SMART issues Monday, April 7, statement on Kilmar Armando Abrego Garcia’s ongoing case
- Local 5 organizes enormous growth in North Carolina
- Make sure your voice is heard, update your contact information
- SMART statement on Kilmar Armando Abrego Garcia’s right to due process
- Union leaders, community supporters to rally Friday, April 4, in support of Kilmar Armando Abrego Garcia and family
- New CSX conductor improvises to save a life
- SMART stands with Kilmar Armando Abrego Garcia
- SMART News: Protecting Railroad Retirees’ Future
- More Than a Story: SMART-TD’s Women’s History Month Highlights Legacies in the Making
- SMART condemns executive order undermining collective bargaining rights